Local Delivery Versus Intracoronary Infusion of Abciximab in Patients With Acute Coronary Syndromes  by Prati, Francesco et al.
L
o
C
F
V
M
R
O
i
u
B
t
M
l
t
T
e
R
c
i
I
s
s
t
d
C
r
d
F
D
W
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 9 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 5 . 0 1 7ocal Delivery Versus Intracoronary Infusion
f Abciximab in Patients With Acute
oronary Syndromes
rancesco Prati, MD,*† Davide Capodanno, MD,‡§ Tomasz Pawlowski, MD,
ito Ramazzotti, MD,* Mario Albertucci, MD,*† Alessio La Manna, MD,‡
arilena Di Salvo, MD,‡ Robert J. Gil, MD, Corrado Tamburino, MD, PHD‡§
ome and Catania, Italy; and Warsaw, Poland
bjectives We investigated whether local abciximab delivery to the site of intracoronary thrombus
s more effective than intracoronary bolus infusion in patients with acute coronary syndromes (ACS)
ndergoing percutaneous coronary intervention and downstream clopidogrel administration.
ackground The intracoronary route of administration does not allow an optimal contact between
he plaque components and abciximab, which is rapidly washed out by the coronary ﬂow.
ethods A total of 50 patients with ACS and a signiﬁcant lesion in the culprit artery indicative of
ocal thrombosis were randomly assigned to receive local intracoronary delivery of abciximab
hrough a dedicated perfusion catheter or intracoronary infusion through the guiding catheter.
he primary end point was the change in thrombus score after angioplasty by optical coher-
nce tomography.
esults After the intervention, the mean percentage change of the thrombus score was signiﬁ-
antly higher among patients of the local delivery group compared with those of the intracoronary
nfusion group (33.8% vs. 3.9%, p  0.002). Post-procedural corrected Thrombolysis in Myocardial
nfarction frame count was shorter in the local delivery group compared with the intracoronary infu-
ion group (15.3  10.2 vs. 21.1  9.9, p  0.049). Procedure-related myocardial infarction was ob-
erved in 10% and 43% of patients in the local delivery and intracoronary infusion groups, respec-
ively (p  0.018). At 1 year, MACE were observed in 5.9% and 27.2% of patients in the local
elivery and intracoronary infusion groups, respectively (p  0.046).
onclusions Local intracoronary delivery of abciximab by means of a dedicated perfusion catheter
educes thrombus burden with the potential to improve coronary microcirculation. (J Am Coll Car-
iol Intv 2010;3:928–34) © 2010 by the American College of Cardiology Foundation
rom the *Interventional Cardiology, San Giovanni Hospital, Rome, Italy; †CLI Foundation, Rome, Italy; ‡Cardiology
epartment, Ferrarotto Hospital, Catania, Italy; §ETNA Foundation, Catania, Italy; and the Klinika Kardiologii Inwazyinej,
arsaw, Poland. The COCTAIL study was sponsored by Atrium Medical Corporation, Hudson, New Hampshire.anuscript received January 25, 2010; revised manuscript received May 5, 2010, accepted May 31, 2010.
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929ost acute coronary syndromes (ACS) are caused by a
hrombus superimposed on a disrupted atherosclerotic
laque leading to sudden complete or partial obstruction of
n epicardial coronary artery (1). Percutaneous coronary
ntervention (PCI) is a well-established therapy for patients
resenting with ACS (2,3). However, a proportion of
atients treated with PCI experience distal embolization
nd microvascular obstruction when the clot is mechanically
islodged and sent downstream, and this event is associated
ith diminished myocardial perfusion and increased mor-
ality (4–6).
See page 935
Adjunctive antiplatelet therapy with the glycoprotein
Ib/IIIa receptor inhibitor abciximab improves epicardial
nd tissue-level perfusion as well as clinical outcomes of
atients undergoing PCI (7–11). Intracoronary administra-
ion of abciximab is associated with additional benefits
ompared with intravenous bolus application (12,13). On
he downside, the intracoronary route of administration
oes not allow an optimal contact between the plaque
omponents and the drug, which is rapidly washed out by
he coronary flow.
The ClearwayRX Therapeutic Perfusion Catheter
Atrium Medical Corporation, Hudson, New Hampshire)
s a micro-porous balloon catheter that acts as a low-
ressure irrigating system for localized perfusion of thera-
eutic agents into the coronary vasculature. We investigated
hether local abciximab delivery to the site of thrombus
hrough the ClearwayRX catheter is more effective than
ntracoronary infusion through the guiding catheter in ACS
atients undergoing PCI.
ethods
tudy design and patient selection. The COCTAIL
ClearwayRx System to reduce intracoronary thrombus in
atients with acute coronary syndromes according to Opti-
al Coherence Tomography after Abciximab Intracoronary
ocal infusion) study was a randomized, open label, multi-
enter trial with blinded assessment of the study end points.
ocal institutional ethical committees approved the study
rotocol, and all participating patients provided informed
onsent. The authors wrote the manuscript and vouch for
he completeness and accuracy of the data gathering and
nalysis. The sponsor had no role in study design, data
ollection, or editing of the final manuscript.
Details on the study protocol have been previously
eported (14). Briefly, the study population consisted of
atients with unstable angina/non–ST-segment elevation
yocardial infarction in which an invasive approach was
lanned and patients with ST-elevation myocardial infarc-
ion (STEMI) undergoing primary PCI. Due to safety ieasons, patients with STEMI were not randomized if the
nfarct-related artery was totally occluded. Other key exclu-
ion criteria are listed in Table 1. Patients were randomized
f they had a significant lesion in the culprit artery indicative
f local thrombosis or haziness suggestive of thrombus.
andomized patients entered the final analysis if they had a
hrombus score 50 according to the optical coherence
omography (OCT) core laboratory.
andomization and treatment. Before PCI, patients were
andomly assigned to receive local delivery of abciximab
hrough the ClearwayRX catheter or intracoronary infusion
f abciximab via the guiding catheter, with the use of a
andomization scheme devised and implemented by the
tudy statistician.
All patients underwent baseline angiography and OCT
ssessment before abciximab administration. Patients in the
ocal delivery group received an intracoronary bolus dose of
bciximab (0.25 mg/kg) delivered with the perfusion cath-
ter, whereas patients in the control-group received the
ame intracoronary bolus dose of abciximab delivered
hrough the guiding catheter.
Both groups received post-
rocedural infusion of abciximab
or the ensuing 12 h at the dos-
ge of 0.125 g/kg/min. All pa-
ients received aspirin 81 to 325
g orally as soon as possible and
aily thereafter, a clopidogrel
00-mg loading dose after the
ompletion of PCI and 75 mg
or at least 30 days after random-
zation (or up to 1 year in case of
rug-eluting stent implanta-
ion), and unfractionated hepa-
in bolus of 40 U/kg (maximum 3,000 U) with dose
djustment to maintain activated clotting time 200 to 250 s
uring the procedure.
nd points and deﬁnitions. The primary end point was the
hange of the thrombus burden defined by the thrombus
core, as detailed in the following text. Secondary end points
ere post-procedural corrected Thrombolysis in Myocardial
nfarction (TIMI) frame count (15), myocardial blush grade
16), procedure-related myocardial infarction (MI), and
0-day and 1-year rates of major adverse cardiac events
MACE). MACE were defined as the composite of death
rom any cause, re-infarction, or target lesion revasculariza-
ion. Procedure-related MI was diagnosed if the creatine
inase-myocardial band level increased to twice the upper
imit of normal or twice the last non-normalized measure-
ent (17).
Coronary angiography was performed before and after
he PCI. The OCT image acquisition was performed before
nd after abciximab administration to document changes
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
OCT  optical coherence
tomography
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis in
Myocardial Infarctionn the thrombus score. The M2 and M3 OCT systems
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930LightLab Imaging, Inc., Westford, Massachusetts) were
sed according to the nonocclusive technique, as previously
escribed (18–21). Briefly, the image wire was positioned in
Figure 1. Thrombus Score
Table 1. Key Exclusion Criteria
Myocardial ischemia precipitated by a condition other than atherosclerotic
disease
Use of a ﬁbrinolytic agent within 14 days before randomization
Use of abciximab or any other glycoprotein IIb/IIIa inhibitor within 30 days
before randomization
Suspected active internal bleeding or history of hemorrhagic diathesis
Major surgery, biopsy of a parenchimal organ, eye surgery, or serious trauma
within 6 weeks before randomization
Gastrointestinal or genitourinary bleeding of clinical signiﬁcance within 6 weeks
before randomization
History of cerebrovascular accident or transient ischemic attack within the previous
2 yrs or any cerebrovascular accident with a residual neurological deﬁcit
Administration of oral anticoagulants within 7 days before randomization unless
prothrombin time 1.2 or less times control (or international normalized ratio
1.4) or ongoing treatment with oral anticoagulant
Known current platelet count 100,000 cells/l
Intracranial neoplasm, arteriovenous malformation, aneurysm, or aneurysm repair
Known allergy to abciximab or other murine proteins
Known positive pregnancy test for women of childbearing ageCase example of thrombus score calculation in a patient excluded from the ﬁnal anahe target vessel, distal to the culprit lesion, and pulled back
t 2 or 3 mm/s speed. Pull-back was performed during
imultaneous hand-made injection of Iodinoxanol 370 (Vi-
ipaque, GE Healthcare, Cork, Ireland) from the guiding
atheter at an infusion rate based on the runoff of the artery
nd the online assessment of the OCT image quality. To
nsure performance of the post-drug infusion acquisition in
he same segment, the image wire was not removed after the
aseline assessment. Offline core laboratory analysis identi-
ed matching cross-sections on the basis of anatomical
andmarks or lumen morphology. Patients with wrong
atched cross-sections were excluded from the analysis.
Thrombus score grading was based on the semi-
uantitative assessment of thrombus (number of involved
uadrants in the cross-sectional OCT images) and the
ongitudinal extension of the thrombus itself (14). By
pplying this method, in each cross-section, a thrombus was
lassified as absent or subtending 1, 2, 3, or 4 quadrants.
ence, the score was calculated as the sum of each cross-
ection score (Fig. 1). Thrombi were identified by OCT as
asses protruding into the vessel lumen and discontinuous
rom the surface of the vessel wall.lysis due to thrombus score 50.
S
e
s
p
l
c
a
I
a
c
v
u
p
t
w
u
2
R
S
s
c
l
(
g
c
w
S
t
c
l
i
d
a
b
t
d
g
T
a
T
r
d
w
c
f
a
f
o
c
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 9 , 2 0 1 0 Prati et al.
S E P T E M B E R 2 0 1 0 : 9 2 8 – 3 4 Perfusion Balloon in ACS Patients
931tatistical analysis. We estimated that we would have to
nroll 40 patients to achieve a power of 80%, with a 2-sided
ignificance level of 0.05, to detect a 25% difference in the
rimary end point reduction in patients who underwent
ocal abciximab delivery through the perfusion catheter as
ompared with those who underwent intracoronary bolus
dministration through the guiding catheter.
All data were processed with SPSS version 15 (SPSS,
nc., Chicago, Illinois). Categorical variables were presented
s counts and percentages and compared by means of the
hi-square test or Fisher exact test when at least 25% of
alues showed an expected cell frequency below 5. Contin-
ous variables were normally distributed and therefore
resented as mean  SD and compared by Student unpaired
test for between-group comparison and paired t test for
ithin-group comparison. The Levene test was used to eval-
ate the homogeneity of the variances. For all analyses, a
-sided p value 0.05 was considered statistically significant.
esults
tudy population. During the study period, 50 of 87
creened patients at 3 sites in Europe matched the eligibility
riteria and, before PCI, were randomly assigned to undergo
ocal delivery of abciximab through the perfusion catheter
n  25) or intracoronary delivery of abciximab through the
Figure 2. Study Flow ChartNine randomized patients did not enter the ﬁnal analysis, because of insufﬁcient imauiding catheter (n  25) (Fig. 2). The baseline clinical
haracteristics, including age and cardiovascular risk factors,
ere well-balanced in the 2 arms of the study (Table 2). A
TEMI was the clinical presentation in 40% of patients in
he local delivery group and 36% of patients in the intra-
oronary infusion group. A total of 43% of patients in the
ocal delivery group and 40% of those in the intracoronary
nfusion group had left anterior descending coronary artery
isease. Minimal lumen diameter, reference vessel diameter,
nd stenosis diameter before intervention did not differ
etween the study groups (Table 3). After the intervention,
he mean residual diameter stenosis was lower in the local
elivery group compared with the intracoronary infusion
roup (5.9  3.3 vs. 11.2  9.1, p  0.022).
hrombus burden. In the local delivery group, no failure to
dvance the device across the culprit lesion was observed.
hrombus score changes were assessed in 41 of the 50
andomized patients (82%). Nine patients (5 in the local
elivery group and 4 in the intracoronary infusion group)
ere excluded for the reasons listed in Figure 2. Clinical
haracteristics of these patients did not significantly differ
rom those of patients randomized and included in the final
nalysis. Patients excluded from the final analysis were
ollowed up at 12 months from the index procedure with
nly 1 target lesion revascularization reported in the intra-
oronary infusion group at 9 months (p  0.444).ge quality, wrong segment matching, or thrombus score 50.
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932In the overall study population, thrombus scores at
aseline and after the procedure were 98.3  50.0 and
7.1  48.9, respectively. The absolute thrombotic burden
efined by the thrombus score was similar at baseline
etween patients in the local delivery group and those in the
ntracoronary infusion group (106.8 50.0 vs. 90.5 48.4,
 0.272). After the procedure, the thrombus score was
8.8  44.8 in the local delivery group and 85.4  52.7 in
Table 2. Baseline Clinical Characteristics
Intracoronary
Abciximab Through
the Perfusion Catheter
(n  25)
Intracoronary
Abciximab Through
the Guiding Catheter
(n  25) p Value
Age 62.7  9.2 64.4  10.3 0.544
Male 18 (72) 17 (68) 0.758
Hypertension 19 (76) 18 (72) 0.747
Diabetes mellitus 9 (36) 7 (28) 0.544
Hyperlipidemia 14 (56) 16 (64) 0.564
Smoking 12 (48) 8 (32) 0.248
Family history 8 (32) 5 (20) 0.333
Prior MI 4 (16) 3 (12) 1.000
Prior CABG 2 (8) 1 (4) 1.000
Clinical presentation 0.816
Unstable angina 3 (12) 2 (8)
NSTEMI 12 (48) 14 (56)
STEMI 10 (40) 9 (36)
Target vessel 0.789
LMT 1 (4) 0 (0)
LAD 9 (36) 10 (40)
LCX 9 (36) 9 (36)
RCA 6 (24) 6 (24)
Values are expressed as mean SD or n (%).
CABG coronary artery bypass graft; LAD left anterior descending; LCX left circumflex;
LMT  left main trunk; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myo-
cardial infarction; RCA right coronary artery; STEMI ST-segment elevationmyocardial infarc-
tion.
Table 3. Procedural Profile and Results of Quantitative
Coronary Angiography
Intracoronary
Abciximab Through
the Perfusion Catheter
(n  25)
Intracoronary
Abciximab Through
the Guiding Catheter
(n  25) p Value
Minimal lumen
diameter, mm
Before angioplasty 0.57 0.38 0.61 0.33 0.779
After angioplasty 2.64 0.34 2.49 0.38 0.201
Reference vessel
diameter, mm
Before angioplasty 2.55 0.52 2.49 0.42 0.617
After angioplasty 2.82 0.40 2.82 0.37 0.921
Diameter stenosis, %
Before angioplasty 78.7 11.5 75.2 13.5 0.444
After angioplasty 5.94 3.27 11.21 9.07 0.022Values are expressed as mean SD.he intracoronary infusion group (p  0.393). As a result,
he absolute change of the thrombus score after the proce-
ure was significant in the local delivery group and not
ignificant in the intracoronary infusion group (Fig. 3).
ccordingly, the mean percentage change of the thrombus
core (primary end point) was significantly higher among
atients of the local delivery group compared with those of the
ntracoronary infusion group (33.8% vs. 3.9%, p  0.002).
yocardial reperfusion and 30-day clinical outcome. In the
ocal delivery group, the post-procedural corrected TIMI
rame count was shorter compared with the intracoronary
nfusion group (15.3  10.2 vs. 21.1  9.9, p  0.049). A
yocardial blush grade of 0 or 1 occurred in no patients of
he local delivery group and in 5.9% patients of the
ntracoronary infusion group (Fig. 4). Post-procedural mean
yocardial blush grade did not differ between groups
2.78  0.43 vs. 2.59  0.62, p  0.303). However,
Figure 3. Pre-Procedural and Post-Procedural Thrombus Scores
Differences of thrombus score between patients who received local abcix-
imab delivery and those who received intracoronary infusion through the
guiding catheter. In the local delivery group, thrombus score signiﬁcantly
varied after the procedure.
100%
65%70%
80%
90%
78%
30%
40%
50%
60%
6%
22%
29%
0%
10%
20%
Perfusion catheter Guiding catheter
3
2
0 or 1
Figure 4. Myocardial Blush Grade According to Treatment Group
The percentages of patients are shown according to myocardial blush
grade on the angiogram.
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933rocedure-related MI was detected in 10% of patients in the
ocal delivery group and 43% of patients in the intracoronary
nfusion group (p  0.018).
There were no clinical events at 30 days in either group.
onversely, at 1 year, MACE were observed in 5.9% of
atients in the local delivery group versus 27.2% of those in
he intracoronary infusion group (p  0.046), driven by a
igher rate of target lesion revascularization in the intra-
oronary infusion group compared with the local delivery
roup (21.6% vs. 5.9%, p  0.126).
iscussion
he results of this randomized trial show that, in patients
ith ACS and evidence of thrombus in the culprit lesion
ndergoing PCI and downstream clopidogrel administra-
ion, local delivery of abciximab at the site of the athero-
hrombotic plaque through a dedicated catheter yields a
reater dissolution of the thrombus burden than conven-
ional intracoronary bolus administration. In particular,
atients who received abciximab through the perfusion
atheter had an almost 30% higher change of thrombus
core after infusion compared with those in the control
roup, as described by OCT. Importantly, these patients
lso had a lower degree of post-procedural stenosis, im-
roved myocardial perfusion as expressed by the corrected
IMI frame count, and lower rates of procedure-related MI
nd 1-year MACE. Overall, these findings suggest the
fficacy of local drug delivery to enhance the contact of
bciximab with the plaque components and imply that the
ash-out of the drug is 1 of the potential mechanisms to
xplain why rates of slow flow remain high in lesions with
igh thrombotic burden, despite intracoronary abciximab
dministration via the guiding catheter.
The interest in combining pharmacological and catheter-
ased invasive therapies to lower the frequency of subopti-
al myocardial reperfusion after PCI has encouraged the
evelopment of various devices to protect the microcircula-
ion. The ClearwayRX Therapeutic Perfusion Catheter acts
s a low-pressure irrigating system for localized perfusion of
herapeutic agents at high concentrations into the coronary
nd peripheral vasculature. Mechanical features of the
elivery catheter are maximized to allow improved drug
elivery throughout the entire length of the balloon by
rolonging the “residence time” of the drug (drug stays in
ontact longer with the thrombotic lesion before being
ashed away) and by facilitating the diffusion of the
ntibody to platelets inside flow-limiting thrombi. This
ight result in improved dissolution of thrombi and micro-
mboli at the culprit lesion and in the distal vessel territory.
Importantly, because the study aimed to assess differences
elated to the route of drug administration, the protocol
equired the use of perfusion devices slightly undersized
ith respect to the luminal diameter of the vessel, on the masis of OCT assessment. This was necessary to avoid the
otential for thrombus dislodgement due to the use of the
erfusion balloon, which could make it difficult to discrim-
nate between therapeutic effect of local abciximab delivery
nd reduced thrombus volume due to the mechanical action
f the device. The potential for a Dotter effect was also
imited or avoided by careful sizing of the perfusion catheter
n the basis of OCT.
This is, to the best of our knowledge, the first study that
ses OCT to grade thrombotic burden in the setting of
CI. Thrombus score was graded with a pre-specified
efinition developed ad hoc and adapted for OCT. Al-
hough OCT is an optimal technique for thrombus visual-
zation, due to its high-resolution modality—which allows
etailed imaging of the superficial components of the
therosclerotic plaque (21)—one might argue that throm-
us dislodgement could be caused by wire insertion and
hereby affect the study results. However, it has been
emonstrated that the amount of thrombus dislodged due
o wire crossing is trivial, because the vast majority of
hrombus embolization is caused by percutaneous transcath-
ter coronary angioplasty and stenting (22). In this study,
he minimal additional risk caused by thrombus dislodge-
ent due to wire crossing was offset because all the
rocedures were accomplished with intracoronary abciximab
dministration. This is in agreement with the observation
hat only 1 patient experienced post-procedural myocardial
lush grade 2 in the intracoronary infusion group, and
o patients had early clinical events at 30 days. In
ddition, patients in the local delivery group experienced
ower rates of procedure-related MI.
tudy limitations. The COCTAIL study was a phase IIb
rial, which aimed to investigate the efficacy of a novel
ystem to enhance intracoronary abciximab delivery. De-
pite 9 of 50 patients being randomized, treated, and then
xcluded from the analysis mainly due to insufficient image
uality or wrong segment matching, the study was powered
or assessing differences relevant to the primary end point.
owever, the potential for introducing bias by excluding
atients who were randomized cannot be entirely ruled out.
herefore, caution should be applied when interpreting the
tudy results. The study was not powered to address
econdary end points, which have been provided to guide
he interpretation of the primary results. Also, information
n clinical outcomes, which are pivotal to prompt the use of
novel investigated device into clinical practice, are limited
y the small sample size. The INFUSE AMI (INFUSE -
nterior Myocardial Infarction) trial (NCT00976521),
hich is currently recruiting participants, will randomize
52 patients with a 2  2 factorial design to investigate the
ombined role of local infusion of abciximab and thrombus
spiration. This study will provide more evidence to support
or discourage) the implementation of a comprehensive
ulti-targeted mechanical and pharmacological approach as
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934strategy aimed to increase the magnitude of the angio-
raphic benefit and put it significantly on the clinical level.
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